These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 33563889)

  • 1. Myeloid malignancies with 5q and 7q deletions are associated with extreme genomic complexity, biallelic TP53 variants, and very poor prognosis.
    Pitel BA; Sharma N; Zepeda-Mendoza C; Smadbeck JB; Pearce KE; Cook JM; Vasmatzis G; Sachs Z; Kanagal-Shamanna R; Viswanatha D; Xiao S; Jenkins RB; Xu X; Hoppman NL; Ketterling RP; Peterson JF; Greipp PT; Baughn LB
    Blood Cancer J; 2021 Feb; 11(2):18. PubMed ID: 33563889
    [No Abstract]   [Full Text] [Related]  

  • 2. Genomic Copy Number Variations in the Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients with del(5q) and/or -7/del(7q).
    Zhang R; Kim YM; Wang X; Li Y; Lu X; Sternenberger AR; Li S; Lee JY
    Int J Med Sci; 2015; 12(9):719-26. PubMed ID: 26392809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of the type of 5q loss with complex karyotype, clonal evolution, TP53 mutation status, and prognosis in acute myeloid leukemia and myelodysplastic syndrome.
    Volkert S; Kohlmann A; Schnittger S; Kern W; Haferlach T; Haferlach C
    Genes Chromosomes Cancer; 2014 May; 53(5):402-10. PubMed ID: 24493299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Genetic defects of chromosome 5q and 7q in myeloid neoplasms].
    Hosono N
    Rinsho Ketsueki; 2019; 60(7):800-809. PubMed ID: 31391370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion.
    Sebaa A; Ades L; Baran-Marzack F; Mozziconacci MJ; Penther D; Dobbelstein S; Stamatoullas A; Récher C; Prebet T; Moulessehoul S; Fenaux P; Eclache V
    Genes Chromosomes Cancer; 2012 Dec; 51(12):1086-92. PubMed ID: 22933333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and molecular profiling of AML patients with chromosome 7 or 7q deletions in the context of
    Abbas HA; Ayoub E; Sun H; Kanagal-Shamanna R; Short NJ; Issa G; Yilmaz M; Pierce S; Rivera D; Cham B; Wing S; Li Z; Hammond D; Jabbour E; Borthakur G; Garcia-Manero G; Andreeff M; Daver N; Kadia T; Konopleva M; DiNardo C; Ravandi F
    Leuk Lymphoma; 2022 Dec; 63(13):3105-3116. PubMed ID: 36089905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of distinctive long noncoding RNA competitive interactions and a six-methylated-gene prognostic signature in acute myeloid leukemia with -5/del(5q) or -7/del(7q).
    Yin X; Huang S; Xu A; Fan F; Chen L; Sun C; Hu Y
    J Cell Biochem; 2020 Feb; 121(2):1563-1574. PubMed ID: 31535409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Del(5q) and MLL amplification in homogeneously staining region in acute myeloblastic leukemia: a recurrent cytogenetic association.
    Herry A; Douet-Guilbert N; Guéganic N; Morel F; Le Bris MJ; Berthou C; De Braekeleer M
    Ann Hematol; 2006 Apr; 85(4):244-9. PubMed ID: 16425025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RAS, FLT3, and TP53 mutations in therapy-related myeloid malignancies with abnormalities of chromosomes 5 and 7.
    Side LE; Curtiss NP; Teel K; Kratz C; Wang PW; Larson RA; Le Beau MM; Shannon KM
    Genes Chromosomes Cancer; 2004 Mar; 39(3):217-23. PubMed ID: 14732923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The 5q deletion size in myeloid malignancies is correlated to additional chromosomal aberrations and to TP53 mutations.
    Stengel A; Kern W; Haferlach T; Meggendorfer M; Haferlach C
    Genes Chromosomes Cancer; 2016 Oct; 55(10):777-85. PubMed ID: 27218649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absence of point mutations within the AML-1 gene in patients with MDS/AML and loss of chromosome 5q or 7.
    Ferrari T; Weber B; Pils S; Harbott J; Borkhardt A
    Ann Hematol; 2001 Feb; 80(2):72-3. PubMed ID: 11261327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic gains and losses influence expression levels of genes located within the affected regions: a study on acute myeloid leukemias with trisomy 8, 11, or 13, monosomy 7, or deletion 5q.
    Schoch C; Kohlmann A; Dugas M; Kern W; Hiddemann W; Schnittger S; Haferlach T
    Leukemia; 2005 Jul; 19(7):1224-8. PubMed ID: 15902281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities.
    Möllgård L; Saft L; Treppendahl MB; Dybedal I; Nørgaard JM; Astermark J; Ejerblad E; Garelius H; Dufva IH; Jansson M; Jädersten M; Kjeldsen L; Linder O; Nilsson L; Vestergaard H; Porwit A; Grønbæk K; Hellström-Lindberg E
    Haematologica; 2011 Jul; 96(7):963-71. PubMed ID: 21719884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis.
    Kulasekararaj AG; Smith AE; Mian SA; Mohamedali AM; Krishnamurthy P; Lea NC; Gäken J; Pennaneach C; Ireland R; Czepulkowski B; Pomplun S; Marsh JC; Mufti GJ
    Br J Haematol; 2013 Mar; 160(5):660-72. PubMed ID: 23297687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide.
    Sugimoto Y; Sekeres MA; Makishima H; Traina F; Visconte V; Jankowska A; Jerez A; Szpurka H; O'Keefe CL; Guinta K; Afable M; Tiu R; McGraw KL; List AF; Maciejewski J
    J Hematol Oncol; 2012 Mar; 5():4. PubMed ID: 22390313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic impact of loss of chromosome 7 material detected by fluorescence in situ hybridization (FISH) in myeloid malignancies.
    El-Menoufy MAM; Mourad ZI; Farahat NM
    J Egypt Natl Canc Inst; 2018 Dec; 30(4):133-138. PubMed ID: 30472199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FISH analysis reveals frequent co-occurrence of 4q24/TET2 and 5q and/or 7q deletions.
    La Starza R; Crescenzi B; Nofrini V; Barba G; Matteucci C; Brandimarte L; Pierini V; Testoni N; Musto P; Paolini S; Gianfelici V; Storlazzi CT; Pierini A; Berchicci L; Gorello P; Mecucci C
    Leuk Res; 2012 Jan; 36(1):37-41. PubMed ID: 21920603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FISH investigation of 5q and 7q deletions in MDS/AML reveals hidden translocations, insertions and fragmentations of the same chromosomes.
    Lessard M; Herry A; Berthou C; Léglise MC; Abgrall JF; Morice P; Flandrin G
    Leuk Res; 1998 Apr; 22(4):303-12. PubMed ID: 9669835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Susceptibility gene for familial acute myeloid leukemia associated with loss of 5q and/or 7q is not localized on the commonly deleted portion of 5q.
    Gao Q; Horwitz M; Roulston D; Hagos F; Zhao N; Freireich EJ; Golomb HM; Olopade OI
    Genes Chromosomes Cancer; 2000 Jun; 28(2):164-72. PubMed ID: 10825001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monosomal karyotype routinely defines a poor prognosis subgroup in acute myeloid leukemia and is frequently associated with TP53 deletion.
    Gaillard JB; Chiesa J; Reboul D; Arnaud A; Brun S; Donadio D; Exbrayat C; Wickenhauser S; Bourquard P; Jourdan E; Lavabre-Bertrand T
    Leuk Lymphoma; 2012 Feb; 53(2):336-7. PubMed ID: 21823831
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.